Abstract: Disclosed herein is a specific method of preparation of Trilaciclib. The said method is to provide an efficacy of a protection free synthetic method of Trilaciclib with less steps and good yields.

Abstract: The present invention discloses a method for maintaining or improving gastrointestinal condition, which includes: administering a lactic acid bacterial composition to a subject in need thereof, wherein the lactic acid bacterial composition comprises: a Lactobacillus paracasei ET-66 strain with a deposition number CGMCC 13514. The present invention also discloses a method for maintaining or improving gastrointestinal condition, which includes: administering a lactic acid bacterial fermentation composition to a subject in need thereof, wherein the lactic acid bacterial fermentation composition comprises: a fermentation product of a Lactobacillus paracasei ET-66 strain.

Abstract: A novel PEGylated lipid and preparation methods thereof, a cationic liposome containing the lipid, a pharmaceutical composition containing the liposome, a formulation and application thereof. The PEGylated lipid can be used for modifying a liposome, and can be further modified and coupled with a targeting group and then used for modifying a liposome to obtain a liposome having the targeting group. Due to the presence of a long-chain PEG and the targeting group on the lipid, the modified liposome can avoid being removed by the reticuloendothelial system in a human body and realize a targeting function. Therefore, when the modified liposome delivers an active drug to cells or a patient, especially when delivering a nucleic acid or anti-tumor drug, the liposome can realize long circulation in vivo and improve the transport efficiency of drug, and has a targeting function, so the therapeutic effect of a drug is improved.

Abstract: The present application provides an antibody fusion protein comprising: i) a multivalent (e.g., bivalent) antibody or antigen-binding fragment thereof specifically recognizing Angiopoietin-2 (Ang2)(“multivalent anti-Ang2 antibody or antigen-binding fragment thereof”), and ii) a vascular endothelial growth factor receptor (VEGFR) component, wherein the multivalent anti-Ang2 antibody or antigen-binding fragment thereof does not inhibit the binding between Ang2 and TEK receptor tyrosine kinase (TIE2). Also provided are methods of making and uses thereof.

Abstract: The invention discloses a preparation method of mogroside and a processing device therefor, which relates to the technical field of sweet glycoside preparation. The device includes a collection cabin, a collection pipe, a peeling assembly and a centrifugal separation assembly, wherein the collection cabin is provided with the peeling assembly, the peeling assembly can peel a fresh fructus momordicae, and a peeled pulp enters the collection cabin so that the collection cabin can transport the pulp to the centrifugal separation assembly; the centrifugal separation assembly includes a separation cabin, a disc, a centrifugal cylinder and a filter pipe, wherein the disc is rotatably arranged in the separation cabin, a plurality of the centrifugal cylinders distributed in a circle are fixed at intervals on an outer peripheral side of the disc, the separation cabin being further provided with a liquid injection head corresponding to the centrifugal cylinder.

Abstract: The present invention relates to a method for separating and purifying tetrahydrocannabivarin (THCV) by means of high-speed countercurrent chromatography, the method comprising: sufficiently shaking a solvent system, leaving same to stand, and separately collecting upper and lower phases; dissolving full-spectrum refined hemp oil in the upper phase, taking the upper phase as a stationary phase and the lower phase as a mobile phase, performing separation by using high-speed countercurrent chromatography to obtain a mixed solution of tetrahydrocannabivarin and the mobile phase, and removing the mobile phase to obtain the tetrahydrocannabivarin. According to the present invention, THCV with a purity of >95% is obtained by separation and purification from full-spectrum refined hemp oil by using high-speed countercurrent chromatography technology for the first time.

Abstract: The present invention relates to engineered chimeric guide RNAs and their uses in systems and methods for gene expression perturbation in eukaryotic cells. Furthermore, the invention also relates to methods for generating a modified T cell using the engineered chimeric guide RNAs of the present application, and to the obtained modified T cell. Also included are methods and pharmaceutical compositions comprising the modified T cell for adoptive therapy and treating a condition, such as cancer, infections or autoimmune diseases.

Abstract: The present invention relates to the conjugation of a tubulysin analog compound to a cell-binding molecule with branched/side-chain linkers for having better delivery of the conjugate compound and targeted treatment of abnormal cells. It also relates to a branched-linkage method of conjugation of a tubulysin analog molecule to a cell-binding ligand, as well as methods of using the conjugate in targeted treatment of cancer, infection and autoimmune disease.

Abstract: The present disclosure relates to a ureteral stent and a preparation method thereof. The ureteral stent has at least one pre-coating formed on its surface and at least one hydrophilic lubricating coating formed on the pre-coating. Preferably, the pre-coating and the hydrophilic lubricating coating are formed by photocuring, thermal curing, chemical reaction, physical adsorption, crystallization or freezing. By means of the technical solutions of the present disclosure, a stable and firm coating is formed on the surface of the ureteral stent with a more complicated shape, the friction force (the friction force of the 30th cycle is small, and the friction force of the 30th cycle/initial friction force is kept within 2 times) of the ureteral stent is greatly reduced, and the lubricating performance is greatly improved.

Abstract: A method for promoting growth of a probiotic microorganism includes cultivating the probiotic microorganism in a growth medium containing a fermented culture of lactic acid bacterial strains that include Lactobacillus salivarius subsp. salicinius AP-32 deposited at the China Center for Type Culture Collection (CCTCC) under CCTCC M 2011127, Lactobacillus plantarum LPL28 deposited at the China General Microbiological Culture Collection Center (CGMCC) under CGMCC 17954, Lactobacillus acidophilus TYCA06 deposited at the CGMCC under CGMCC 15210, and Bifidobacterium longum subsp. infantis BLI-02 deposited at the CGMCC under CGMCC 15212.

Abstract: The present invention relates to a medical use of honokiol, and in particular to a use of honokiol in the preparation of a drug for treating a meningioma. Experiments prove that honokiol can effectively inhibit the growth of a meningioma, and eliminate and/or reduce lesions of the meningioma. Moreover, clinical experiments show that the safety and tolerance of honokiol are good.

Abstract: Provided herein are safe harbor loci that can be utilized as sites for genetic modification. Safe harbor loci of the disclosure are shown to support sustained transgene expression with minimal silencing, and minimal impact on local or global gene expression. Safe harbor loci disclosed herein can be used in various genetic and cell engineering applications.

Abstract: The present invention belongs to the field of formulation of a recombinant adeno-associated virus vector, in particular relating to a pharmaceutical composition of a recombinant adeno-associated virus vector, comprising a recombinant adeno-associated virus (rAAV), an ion salt, a buffering agent, a stabilizer, and a surfactant, and its use. The rAAV vector carries hFIX and can be used to treat hemophilia B. The pharmaceutical composition can be stored at a refrigeration temperature, such as 2-8° C., for more than 1 year, maintain stable for such as genome titer and biological activity, and also has good stability when stored at room temperature for two weeks.

Abstract: The present invention discloses a detection apparatus, comprising a base layer, wherein the base layer comprises a groove for containing a testing element and a sample chamber for collecting a fluid sample. The detection apparatus can achieve fast, efficient and accurate detection of analytes in liquid samples, make operators to perform testing conveniently and freely, without causing incorrect results. In some preferred modes, the sample chamber comprises a liquid channel.

Abstract: The invention discloses a carbon fiber composite artificial bone and a preparation method thereof. The artificial bone includes a carbon fiber composite spring-like frame or includes a carbon fiber composite spring-like frame and a carbon fiber composite plate dowel, and the carbon fiber composite plate dowel is inserted into one end or both ends of a cavity of the spring-like frame or penetrates through the cavity of the carbon fiber composite spring-like frame. The preparation method includes: preparing a spring-like carbon fiber preform through a weaving technology by using carbon fibers as a raw material, performing densification and high-temperature purification treatment and preparing a wear-resistant coating to obtain the carbon fiber composite spring-like frame; and combining the carbon fiber composite spring-like frame with the carbon fiber composite plate bowel to obtain the artificial bone.

Abstract: Provided is a dual recombinant viral vector system for expressing, in a cell, a polypeptide molecule which is composed of two different peptide chains and has an antigen binding activity, wherein the first chain is expressed using a first viral vector, the second chain is expressed using a second viral vector, and the first and second chains can be assembled, after being expressed in a cell, into the polypeptide molecule which has an antigen binding activity. Further provided are a dual plasmid system for the production of the dual recombinant viral vector system, a host cell containing the dual recombinant viral vector system, a pharmaceutical composition, and the use of and the method for delivering the polypeptide molecule to a subject by using the dual recombinant viral vector system.

Abstract: A monoclonal antibody specifically binding to human and monkey CD38 antigens or a derivative thereof includes: antigen complementarity-determining regions CDR1, CDR2 and CDR3 of an antibody light chain variable region having amino acid sequences as set forth in SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, respectively; and antigen complementarity-determining regions CDR1, CDR2 and CDR3 of an antibody heavy chain variable region having amino acid sequences as set forth in SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10, respectively. The monoclonal antibody or derivative thereof can be used as a component of a pharmaceutical composition or prepared into a suitable pharmaceutical preparation, administered alone or combined with other therapeutic means such as chemotherapy drugs, for treating tumors with positive CD38 expression, such as human myeloma and human lymphoma.